De-escalating Treatment for HER2-Positive Metastatic Breast Cancer

We are studying whether reducing treatment is safe for patients with undetectable cancer levels after long-term therapy. This trial aims to assess the impact on survival and quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Herceptin
Herceptin is a medicine used to treat certain types of breast and stomach cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pertuzumab
Pertuzumab is a targeted antibody used to treat HER2-positive breast cancer by blocking signals that help tumor cells grow.
Trastuzumab
Trastuzumab is a substance that targets HER2 proteins to treat certain HER2-positive breast and stomach cancers.
Trastuzumab Deruxtecan
Trastuzumab deruxtecan is a targeted cancer treatment that attacks tumors with high HER2 protein levels.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Herwenda
Herzuma
Kadcyla

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut De Cancerologie De L Ouest
Oncologie
Angers, France
Centre Hospitalier Annecy Genevois
Oncologie
Annecy, France
Institut De Cancerologie De L Ouest
Oncologie
Avignon, France

Sponsor: Unicancer
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.